Tests a new iodine scan for finding spread of thyroid cancer
Compares an iodine-124 PET/CT scan with usual iodine scans in people with thyroid cancer.
Plain-language title generated from the registry record
Registry title: Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
Key facts
- Where
- San Francisco, United StatesSee the site
- Phase
- Phase 2
Where in United States
- University of California San FranciscoSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Thomas Hope
- Trial code
- NCT06961084
- Record updated
- 18 June 2026
- Original description
Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.Read full original descriptionShow less
Comparison of I-124 PET/CT to I-123 Whole Body Imaging for the Diagnosis of Thyroid
Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.
Inclusion: Age >= 13 years; Histopathologically confirmed differentiated or poorly differentiated thyroid cancer; Meeting criteria for one of the following two populations:; American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131; Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy; Undergone total thyroidectomy; Planned I-123 imaging within 45 days after enrollment; Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion: Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation; Known pregnancy.